BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23246719)

  • 1. Inflammation alters HDL composition and function: implications for HDL-raising therapies.
    Marsche G; Saemann MD; Heinemann A; Holzer M
    Pharmacol Ther; 2013 Mar; 137(3):341-51. PubMed ID: 23246719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological activities of HDL subpopulations and their relevance to cardiovascular disease.
    Camont L; Chapman MJ; Kontush A
    Trends Mol Med; 2011 Oct; 17(10):594-603. PubMed ID: 21839683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research.
    Triolo M; Annema W; Dullaart RP; Tietge UJ
    Biomark Med; 2013 Jun; 7(3):457-72. PubMed ID: 23734809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of high-density lipoprotein metabolism.
    Rye KA; Barter PJ
    Circ Res; 2014 Jan; 114(1):143-56. PubMed ID: 24385508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.
    Kontush A; Chapman MJ
    Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation, high-density lipoprotein and cardiovascular dysfunction.
    Haas MJ; Mooradian AD
    Curr Opin Infect Dis; 2011 Jun; 24(3):265-72. PubMed ID: 21326098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL.
    Cao P; Pan H; Xiao T; Zhou T; Guo J; Su Z
    Int J Mol Sci; 2015 Jul; 16(8):17245-72. PubMed ID: 26225968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysfunctional HDL: from structure-function-relationships to biomarkers.
    Riwanto M; Rohrer L; von Eckardstein A; Landmesser U
    Handb Exp Pharmacol; 2015; 224():337-66. PubMed ID: 25522994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual effect of hypochlorite in the modification of high density lipoproteins.
    Pirillo A; Uboldi P; Catapano AL
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):447-51. PubMed ID: 21094143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling by the high-affinity HDL receptor scavenger receptor B type I.
    Saddar S; Mineo C; Shaul PW
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):144-50. PubMed ID: 20089950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-density lipoprotein therapeutics and cardiovascular prevention.
    Fazio S; Linton MF
    J Clin Lipidol; 2010; 4(5):411-9. PubMed ID: 21122685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Consequences of Dysfunctional HDL.
    Pirillo A; Catapano AL; Norata GD
    Curr Med Chem; 2019; 26(9):1644-1664. PubMed ID: 29848265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
    Kontush A; Chapman MJ
    Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-density lipoproteins: a consensus statement from the National Lipid Association.
    Toth PP; Barter PJ; Rosenson RS; Boden WE; Chapman MJ; Cuchel M; D'Agostino RB; Davidson MH; Davidson WS; Heinecke JW; Karas RH; Kontush A; Krauss RM; Miller M; Rader DJ
    J Clin Lipidol; 2013; 7(5):484-525. PubMed ID: 24079290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDL particle functionality as a primary pharmacological target for HDL-based therapies.
    Kypreos KE; Gkizas S; Rallidis LS; Karagiannides I
    Biochem Pharmacol; 2013 Jun; 85(11):1575-8. PubMed ID: 23500547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory investigation of dysfunctional HDL.
    Guo ZG; Li C; Zhong JK; Tu Y; Xie D
    Chem Phys Lipids; 2012 Jan; 165(1):32-7. PubMed ID: 22064068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies.
    Toth PP
    Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.
    Riwanto M; Landmesser U
    J Lipid Res; 2013 Dec; 54(12):3227-43. PubMed ID: 23873269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Laboratory assessment of HDL heterogeneity and function].
    Movva R; Rader DJ
    Ann Biol Clin (Paris); 2009; 67(1):7-21. PubMed ID: 19189882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.